0.00Open0.00Pre Close0 Volume0 Open Interest55.00Strike Price0.00Turnover126.57%IV-9.32%PremiumDec 20, 2024Expiry Date4.69Intrinsic Value100Multiplier26DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.5348Delta0.0234Gamma5.27Leverage Ratio-0.1272Theta-0.0230Rho-2.82Eff Leverage0.0534Vega
Janux Therapeutics Stock Discussion
lets go …. 79 solid pt and opportunities for profits off the current value (46.00)
Janux Therapeutics Inc. (NASDAQ: JANX)
Janux Therapeutics is a clinical-stage bioph...
In there, I’ll be sharing more in-depth stock analysis, including entry and target points, plus detailed descriptions of each stock. It’d be great if you all could join us there!
In the meantime, here’s our mid-month update on some stocks I’m keeping an eye on! Let’s aim f...
$Merck & Co (MRK.US)$ already has an active partnership with $Janux Therapeutics (JANX.US)$ for two TRACtr targets, and CEO Davis has evinced a preference for acquisition of $SPDR S&P Biotech ETF (XBI.US)$ in which $Merck & Co (MRK.US)$ already has a seat at the table.
$Merck & Co (MRK.US)$ acquisition of $HARP earlier this year (for a song) shows their interest in the T Cell engag...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$